Hugel launches botulinum toxin Letybo in Malaysia

- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops

- It will solidify the market position of premium toxin products through Malaysian partner Venusys Medical

SEOUL, South Korea, Aug. 10, 2025 /PRNewswire/ -- Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, has officially launched its botulinum toxin product Letybo in Malaysia – an emerging market for medical aesthetics in Southeast Asia.

The company's Malaysian partner Venusys Medical Sdn Bhd introduced Letybo at the Aesthetic Medicine & Surgery Conference & Exhibition (AMSC), the largest medical aesthetics conference in Malaysia, held from August 6 to 7.

Konstantin Frank, a key opinion leader for Letybo in Europe, delivered a presentation at the event, highlighting the precise treatment outcomes of botulinum toxin procedures and sharing clinical strategies to enhance procedural results.

A brand launch event and hands-on workshop followed on August 8 at The Zenith Hotel Kuantan, with around 100 local medical professionals in attendance. The workshop served as a training program focused on botulinum toxin injection techniques that integrate anatomical understanding with clinical expertise.

Venusys Medical, headquartered in Malaysia and operating across Malaysia and Singapore, is a distributor of medical aesthetic products and a long-standing partner of various global brands.

"We will continue to offer customized training programs for local medical professionals in Malaysia through our strategic collaboration with Venusys Medical," a Hugel official said. "We aim to enhance the customer experience of our premium toxin brand and accelerate its market penetration to solidify our position in the region."

About Hugel
Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. As the market leader in injectable aesthetics in South Korea, Hugel is the only South Korean company with regulatory approvals in the world's three largest botulinum toxin markets: the US, China, and Europe. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs, and dynamic industry forums. Over the past 20 years, the company has built a presence in approximately 70 countries and operates nine global subsidiaries across the US, Australia, Canada, Taiwan, Mainland China, Hong Kong, Singapore, and Thailand. Leveraging strong industry momentum, Hugel is well-positioned for continued growth and market expansion worldwide.

Contact:
Jihyun Kim, Manager of the PR Team, Hugel
[email protected] 

SOURCE Hugel